4//SEC Filing
MILLS ROBERT S 4
Accession 0001213900-21-008966
CIK 0001733413other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 4:05 PM ET
Size
9.0 KB
Accession
0001213900-21-008966
Insider Transaction Report
Form 4
MILLS ROBERT S
Director
Transactions
- Exercise/Conversion
Common Stock
2021-02-10$2.50/sh+700$1,750→ 16,680 total - Sale
Common Stock
2021-02-10$20.16/sh−700$14,112→ 15,980 total - Exercise/Conversion
Stock Options (Right to Buy)
2021-02-10−700→ 151,319 totalExercise: $2.50From: 2019-09-26Exp: 2028-09-26→ Common Stock (700 underlying)
Footnotes (3)
- [F1]The transactions reported by this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020.
- [F2]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F3]36,005 shares of common stock vested on September 26, 2019 and the remainder of the shares vested at an approximate rate of 9,001 every three months thereafter.
Documents
Issuer
TFF Pharmaceuticals, Inc.
CIK 0001733413
Entity typeother
Related Parties
1- filerCIK 0001240140
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 4:05 PM ET
- Size
- 9.0 KB